Truist Securities Downgrades Corcept Therapeutics (CORT) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.22 --0%
Rating Summary:
8 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 19 | New: 2
Rating Summary:
8 Buy, 8 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 19 | New: 2
Join SI Premium – FREE
Truist Securities analyst Gregory Fraser downgraded Corcept Therapeutics (NASDAQ: CORT) from Buy to Hold with a price target of $30.00.
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $28.66 yesterday.
You May Also Be Interested In
- Corcept Therapeutics (CORT) PT Raised to $173 at Piper Sandler
- Morgan Stanley Downgrades Cogna Educacao SA (COGN3:BZ) to Equalweight
- Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
